Medicare’s new $50-a-month deal on weight-loss drugs comes with a catch buried in the fine print of how Part D counts spending. The flat copay makes the medications far cheaper up front, but the money spent on them does not count toward the Part D deductible or the annual out-of-pocket cap — the $2,100 ceiling in 2026 that rises to a projected $2,400 in 2027. For a retiree who also takes other prescriptions, that quirk can quietly push total drug spending higher than the low copay suggests.
The Bridge Program Sits Outside Part D on Purpose
The arrangement is a temporary demonstration, not a permanent Part D benefit, and that structure is the source of the catch. Beginning July 1, 2026 and scheduled to run through the end of 2027, the program lets eligible Part D members who meet medical criteria for weight management pay a flat $50 monthly copay for covered GLP-1 medications. The copay stays the same regardless of the drug’s list price or how much a member has already spent that year, which is the headline appeal of the offer.
The reason the spending does not count is that the demonstration operates alongside Part D rather than inside it. Because the medications are furnished through the separate bridge rather than as a normal covered Part D drug, the dollars a member pays never enter the Part D ledger that tracks progress toward the deductible and the spending cap. As AARP’s explanation of the program lays out, the $50 payments are walled off from the totals that otherwise move a beneficiary toward catastrophic protection.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Why the Cap Exclusion Costs More Than It Looks
The out-of-pocket cap is one of the most valuable protections in Medicare drug coverage, and understanding what it does explains why the exclusion stings. Under the current rules described in Medicare’s Part D cost guidance, once a member’s out-of-pocket spending on covered drugs reaches the annual cap, the plan pays the full cost of those drugs for the rest of the year. The cap is $2,100 in 2026 and is projected to reach $2,400 in 2027, the two years the bridge program spans.
Keeping the GLP-1 copays outside that tally changes the math for anyone with more than one prescription. A retiree who also takes drugs for diabetes, heart disease, or another chronic condition would normally see every out-of-pocket dollar count toward the cap, reaching the point where the plan pays everything sooner. The $50 GLP-1 payments do not help close that gap, so those other drug costs must reach the ceiling entirely on their own, and the total the household spends across all medications ends up higher than a glance at the low copay implies.
The exclusion reaches the front end of coverage too, not just the ceiling. The payments also do not count toward the Part D deductible, so a member cannot lean on the weight-loss copays to satisfy the amount that must be paid before regular drug coverage begins. Both ends of the Part D spending structure — the deductible that opens coverage and the cap that closes out-of-pocket exposure — treat the $50 payments as if they never happened.
A concrete case makes the gap visible. A retiree who spends $2,100 out of pocket on other covered drugs in 2026 reaches the cap on those alone and pays nothing more for them the rest of the year. If several hundred dollars of that person’s annual drug spending instead runs through the $50 GLP-1 copays, none of it counts, so the remaining covered drugs must still reach the full $2,100 on their own. The weight-loss payments sit entirely on top of the ceiling rather than helping to meet it.
Weighing the $50 Copay Against the Lost Credit
For many members the trade still favors taking the deal, but only after the full picture is clear. Fifty dollars a month is a fraction of the list price of these drugs, and someone who takes few other prescriptions loses little by not having the spending counted, because they were unlikely to approach the cap anyway. The exclusion bites hardest for high-utilizers — those already on several expensive medications who would otherwise cross the cap and stop paying out of pocket partway through the year.
The demonstration’s temporary nature adds another layer to the decision. The program is authorized only through the end of 2027, and a nonpartisan analysis of the model notes that federal officials plan to study its use before deciding whether any broader coverage follows. That means the $50 price and its out-of-pocket exclusion are both features of a limited test, not settled Medicare policy a retiree can count on indefinitely.
The practical takeaway is to treat the copay and the cap as two separate questions rather than one. The low monthly price is real and, for many, worth taking; the lost credit toward the deductible and the cap is a quieter cost that lands mostly on those with heavy overall drug spending. Anyone deciding whether to enroll should tally their other prescriptions first, because the number that determines whether the exclusion matters is not the $50 copay but how close their remaining drugs would have carried them to the ceiling on their own.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
